The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Top NHL highlights from ASH 2024 & trials to look out for in 2025: expert insights
In this exclusive video compilation, hear directly from leading experts as they share their top highlights in non-Hodgkin lymphoma (NHL) from the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. This roundup features:
• Manali Kamdar, who highlights valuable clinical trials, including the POLARIX trial (NCT03274492), the AMPLIFY trial (NCT03836261), and exciting novel agents and combinations being explored in follicular lymphoma (FL);
• Paolo Strati, who discusses updates in relapsed/refractory (R/R) FL, specifically the value of targeting CD19;
• Tycel Phillips, who summarizes key studies in large B-cell lymphoma (LBCL) and FL;
• Krish Patel, who highlights practice-changing trials in mantle cell lymphoma (MCL), namely the GLOBRYTE trial (EU CT: 2023-503206-37-00) and the BRUIN MCL-321 trial (NCT04662255);
• Nirav Shah, who discusses promising combinations with R-CHOP in LBCL, referencing the five-year POLARIX data.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
